David Granger
Vice President - Research & Development NovalGen
Dr David Granger has over 15 years’ experience in drug discovery, working on both small molecule and antibody therapeutic programmes. Originally trained as a pharmacologist he joined global pharmaceutical company GSK following a PhD and post-doctoral research position at Imperial College. At GSK David led bispecific antibody programmes utilising different discovery platforms and overseeing various collaborations. In 2017, he joined bispecific antibody biotechnology company Crescendo Biologics as a Senior Scientist, leading therapeutic immuno-oncology programmes, and developing and embedding a bispecific discovery platform into the workflow. David joined NovalGen in 2019 where he leads the R&D team with activities spanning from target identification and antibody discovery through to translational research and IND-enabling studies.
Seminars
- Addressing how TCEs are showing great efficacy in clinic but remain toxic hindering broader patient access and community use
- Showcasing NovalGen’s AutoRegulation (AR) platform: safeguarding potency and efficacy while preventing T cell exhaustion through built-in self-regulation
- Advancing the world’s first AR-enabled TCE toward the clinic by end of 2025
